Jump to Main Content

FDA Alerts

Safety Information on Varubi (Rolapitant) Injectable Emulsion

The Oncology Center of Excellence of the U.S. Food and Drug Administration is informing health care providers about new safety information for VarubiĀ® (rolapitant) injectable emulsion, a substance P/neurokinin (NK-1) receptor antagonist indicated for the prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults.